{"disease":{"id":"chorioretinal-vascular-disease","name":"chorioretinal vascular disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03767738","title":"Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05704725","title":"A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05986786","title":"Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Alvotech Swiss AG","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}